Background There is comparatively little information in the public domain on the diversity in
prevalence and triggers/factors associated with allergic rhinitis (AR) or allergic …

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic
COPD and allergic rhinitis are a global health concern. Despite the coexistence of these …

Abstract In 2004 the World Allergy Organization's Specialty and Training Council conducted
a survey of World Allergy Organization (WAO) member societies to obtain information about …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. We assessed its efficacy and …

Background Elevated numbers of blood eosinophils are a risk factor for asthma
exacerbations. Reslizumab is a humanised anti-interleukin 5 monoclonal antibody that …

Background Dupilumab is a fully human anti–interleukin-4 receptor α monoclonal antibody
that blocks both interleukin-4 and interleukin-13 signaling. Its effectiveness in reducing oral …

Background Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have
a high symptom burden and poor health-related quality of life, often requiring recurring …

Background Dupilumab, a fully human anti-interleukin-4 receptor α monoclonal antibody,
inhibits interleukin-4 and interleukin-13 signalling, key drivers of type-2-mediated …

Abstract Background Monoclonal antibodies targeting IgE, interleukin-4 and-13, and
interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed …

Background Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the
general population, and long-term use of systemic corticosteroids is associated with adverse …